Euroapi, a leading player in the pharmaceutical industry, is headquartered in France and operates across major regions in Europe and beyond. Founded in 2022, the company has quickly established itself as a key provider of active pharmaceutical ingredients (APIs) and advanced drug delivery systems. With a focus on innovation and sustainability, Euroapi offers a diverse range of products and services that cater to the evolving needs of the healthcare sector. Their commitment to quality and regulatory compliance sets them apart in a competitive market. Recognised for their expertise in complex APIs, Euroapi has achieved significant milestones, positioning itself as a trusted partner for pharmaceutical companies worldwide. As the industry continues to evolve, Euroapi remains dedicated to advancing healthcare solutions through cutting-edge technology and strategic collaborations.
How does Euroapi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Euroapi's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Euroapi reported total carbon emissions of approximately 96,472,000 kg CO2e, a decrease from about 107,454,000 kg CO2e in 2023. The emissions data for 2022 indicates a total of 91,378,000 kg CO2e, which includes 61,317,000 kg CO2e from Scope 1 and 30,061,000 kg CO2e from Scope 2, alongside significant Scope 3 emissions of approximately 590,577,000 kg CO2e. Euroapi has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Additionally, they have established a more aggressive target of a 42% reduction in these scopes by 2030, relative to a 2022 baseline. For Scope 3 emissions, the company aims for a 25% reduction by 2030. Looking further ahead, Euroapi has committed to achieving net-zero carbon emissions by 2050, targeting a 90% reduction across all scopes compared to 2022 levels. These targets align with the Science Based Targets initiative (SBTi) and reflect Euroapi's commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 74,043,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 2 | 40,003,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 3 | - | 000,000,000 | 000,000,000 | - | - |
Euroapi's Scope 3 emissions, which decreased by 8% last year and decreased by approximately 8% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 48% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Euroapi has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Euroapi's sustainability data and climate commitments